Nitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chief Executive Officer, Expands Series A to $45M, and Changes Company Name to Nitrase Therapeutics

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3nVHcD9
via IFTTT